Vlado Perkovic's Publications

Li JW, Woodward M, Perkovic V et alii
Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes

Journal articles
2020
JACC: Heart Failure
Levey AS, Gansevoort RT, Coresh J et alii
Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency

Conference Papers
2020
in American Journal of Kidney Diseases
Neal B, Li J, Perkovic V et alii
An exploration of factors mediating the effects of canagliflozin on heart failure in patients with type 2 diabetes

Conference Papers
2019
in DIABETOLOGIA
Rahimi K, Canoy D, Nazarzadeh M et alii
Investigating the stratified efficacy and safety of pharmacological blood pressure-lowering: An overall protocol for individual patient-level data meta-analyses of over 300 000 randomised participants in the new phase of the Blood Pressure Lowering Treatment Trialists' Collaboration (BPLTTC)

Journal articles
2019
BMJ Open
Perkovic V, Bain S, Bakris G et alii
EFFECTS OF SEMAGLUTIDE AND LIRAGLUTIDE ON URINARY ALBUMIN-TO-CREATININE RATIO (UACR) - A POOLED ANALYSIS OF SUSTAIN 6 AND LEADER

Conference Papers
2019
in NEPHROLOGY DIALYSIS TRANSPLANTATION
Perkovic V, Bain S, Bakris G et alii
EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUES SEMAGLUTIDE AND LIRAGLUTIDE ON RENAL OUTCOMES - A POOLED ANALYSIS OF THE SUSTAIN 6 AND LEADER TRIALS

Conference Papers
2019
in NEPHROLOGY DIALYSIS TRANSPLANTATION
Perkovic V, Bain S, Bakris G et alii
EGFR LOSS WITH GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUE TREATMENT: DATA FROM SUSTAIN 6 AND LEADER

Conference Papers
2019
in NEPHROLOGY DIALYSIS TRANSPLANTATION
Oshima M, Ohkuma T, Neal B et alii
DIFFERENT EGFR THRESHOLDS AND THE RENAL EFFECTS OF CANAGLIFLOZIN: DATA FROM THE CANVAS PROGRAM

Conference Papers
2019
in NEPHROLOGY DIALYSIS TRANSPLANTATION
Smyth B, Trongtrakul K, Haber A et alii
Inequities in the global representation of sites participating in large, multicentre dialysis trials: A systematic review

Journal articles
2019
BMJ Global Health
Bello AK, Levin A, Lunney M et alii
Status of care for end stage kidney disease in countries and regions worldwide: International cross sectional survey

Journal articles
2019
The BMJ
Neuen BL, Cherney DZ, Jardine MJ et alii
Sodium-glucose cotransporter inhibitors in type 2 diabetes: Thinking beyond glucose lowering

Journal articles
2019
CMAJ
Inagaki N, Yang W, Watada H et alii
Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA® trial

Journal articles
2019
Diabetology International
Smyth B, van den Broek-Best O, Hong D et alii
Varying association of extended hours dialysis with quality of life

Journal articles
2019
Clinical Journal of the American Society of Nephrology
Neuen BL, Young T, Heerspink HJL et alii
SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis

Journal articles
2019
The Lancet Diabetes and Endocrinology
Perkovic V, Bain SC, Bakris G et alii
Estimated GFR (eGFR) loss with glucagon-like peptide-1 (GLP-1) analogue treatment: data from SUSTAIN 6 and LEADER

Conference Papers
2019
in DIABETOLOGIA
Neuen BL, Perkovic V, Ohkuma T et alii
Canagliflozin in patients with type 2 diabetes and macroalbuminuria: data from the CANVAS program

Conference Papers
2019
in DIABETOLOGIA
Mahaffey KW, Li J, Badve SV et alii
The effects of canagliflozin on uric acid and gout in patients with type 2 diabetes in the CANVAS programme

Conference Papers
2019
in DIABETOLOGIA
Jardine MJ, Mahaffey KW, Perkovic V
Canagliflozin and Renal Outcomes in Diabetic Nephropathy. Reply

Journal articles
2019
The New England journal of medicine
Neuen BL, Ohkuma T, Neal B et alii
Effect of canagliflozin on renal and cardiovascular outcomes across different levels of albuminuria: Data from the CANVAS program

Journal articles
2019
Journal of the American Society of Nephrology
Inker LA, Heerspink HJL, Tighiouart H et alii
GFR slope as a surrogate end point for kidney disease progression in clinical trials: A meta-analysis of treatment effects of randomized controlled trials

Journal articles
2019
Journal of the American Society of Nephrology
Mahaffey KW, Jardine MJ, Bompoint S et alii
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups

Journal articles
2019
Circulation
Ha JT, Neuen BL, Cheng LP et alii
Benefits and harms of oral anticoagulant therapy in chronic kidney disease

Journal articles
2019
Annals of Internal Medicine
Atkins ER, Perkovic V
Blood pressure: At what level is treatment worthwhile?

Journal articles
2019
Australian Prescriber
Zhou Z, Jardine M, Perkovic V et alii
Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program

Journal articles
2019
Diabetologia
Zhan Z, Smyth B, Toussaint ND et alii
Effect of extended hours dialysis on markers of chronic kidney disease-mineral and bone disorder in the ACTIVE Dialysis study

Journal articles
2019
BMC Nephrology
Oshima M, Jun M, Ohkuma T et alii
The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study

Journal articles
2019
Diabetologia

Vlado Perkovic's Publications

Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes

Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency

An exploration of factors mediating the effects of canagliflozin on heart failure in patients with type 2 diabetes

Investigating the stratified efficacy and safety of pharmacological blood pressure-lowering: An overall protocol for individual patient-level data meta-analyses of over 300 000 randomised participants in the new phase of the Blood Pressure Lowering Treatment Trialists' Collaboration (BPLTTC)

EFFECTS OF SEMAGLUTIDE AND LIRAGLUTIDE ON URINARY ALBUMIN-TO-CREATININE RATIO (UACR) - A POOLED ANALYSIS OF SUSTAIN 6 AND LEADER

EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUES SEMAGLUTIDE AND LIRAGLUTIDE ON RENAL OUTCOMES - A POOLED ANALYSIS OF THE SUSTAIN 6 AND LEADER TRIALS

EGFR LOSS WITH GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUE TREATMENT: DATA FROM SUSTAIN 6 AND LEADER

DIFFERENT EGFR THRESHOLDS AND THE RENAL EFFECTS OF CANAGLIFLOZIN: DATA FROM THE CANVAS PROGRAM

Inequities in the global representation of sites participating in large, multicentre dialysis trials: A systematic review

Status of care for end stage kidney disease in countries and regions worldwide: International cross sectional survey

Sodium-glucose cotransporter inhibitors in type 2 diabetes: Thinking beyond glucose lowering

Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA® trial

Varying association of extended hours dialysis with quality of life

SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis

Estimated GFR (eGFR) loss with glucagon-like peptide-1 (GLP-1) analogue treatment: data from SUSTAIN 6 and LEADER

Canagliflozin in patients with type 2 diabetes and macroalbuminuria: data from the CANVAS program

The effects of canagliflozin on uric acid and gout in patients with type 2 diabetes in the CANVAS programme

Canagliflozin and Renal Outcomes in Diabetic Nephropathy. Reply

Effect of canagliflozin on renal and cardiovascular outcomes across different levels of albuminuria: Data from the CANVAS program

GFR slope as a surrogate end point for kidney disease progression in clinical trials: A meta-analysis of treatment effects of randomized controlled trials

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups

Benefits and harms of oral anticoagulant therapy in chronic kidney disease

Blood pressure: At what level is treatment worthwhile?

Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program

Effect of extended hours dialysis on markers of chronic kidney disease-mineral and bone disorder in the ACTIVE Dialysis study

The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study

The George Institute for Global Health

The George Institute country sites:

Affiliation/s

Acknowledgement of Country